Global Information
회사소개 | 문의 | 비교리스트

세계의 자가혈당측정기 시장(2012-2024년)

Global Self-monitoring Blood Glucose Market - Growth, Trends and Forecast (2020 - 2025)

리서치사 Mordor Intelligence LLP
발행일 상품 코드 808259
페이지 정보 영문
가격
US $ 4,250 ₩ 5,230,000 PDF by E-mail (Single User License)
US $ 4,750 ₩ 5,846,000 PDF by E-mail (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,384,000 PDF by E-mail (Site License)
US $ 7,500 ₩ 9,231,000 PDF by E-mail (Corporate License)


세계의 자가혈당측정기 시장(2012-2024년) Global Self-monitoring Blood Glucose Market - Growth, Trends and Forecast (2020 - 2025)
발행일 : 페이지 정보 : 영문

세계에서 가장 급증하고 있는 만성질환 중 하나가 당뇨병입니다. 당뇨병은 혈당치가 정상적인 레벨을 넘어 상승하고 인슐린을 분비하는 능력이 저하하여 발생하는 질환입니다. 이에 따라 혈당치를 감시하기 위해 혈당측정기가 사용됩니다. 세계에서 1형 당뇨병 환자가 증가하고 있습니다. 당뇨병 환자의 증가에 의해 이 시장의 성장이 촉진되고 있습니다.

세계의 자가혈당측정기(Self-Monitoring Blood Glucose) 시장을 조사했으며, 시장 개요, 컴포넌트·최종사용자·지역별 시장 규모의 추이와 예측, 시장 성장요인 및 저해요인, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 조사 결과
  • 전제조건
  • 조사 범위

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 성장요인
  • 저해요인
  • Porter의 산업 분석
    • 바이어의 교섭력
    • 공급 기업의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 경쟁 기업 간 경쟁 관계

제5장 시장 세분화

  • 자가혈당측정기(Self-blood Glucose Monitors) 시장
    • 컴포넌트별
      • 혈당측정기(Glucometer Devices)
      • 테스트 스트립
      • 란셋
    • 최종사용자별
      • 병원
      • 개인
    • 지역별
      • 북미
      • 유럽
      • 라틴아메리카
      • 아시아태평양
      • 중동·아프리카

제6장 시장 지표

  • 1형 당뇨병 환자의 추이와 예측
  • 2형 당뇨병 환자의 추이와 예측

제7장 경쟁 구도

  • 기업 개요
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 기업 점유율 분석
    • Roche
    • Johnson & Johnson
    • Abboott Diabetes Care
    • 기타

제8장 시장 기회와 전망

KSA 19.03.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

The Global Self-monitoring Blood Glucose market is expected to register a CAGR above 8% during the forecast period (2020-2025), and the market is estimated to reach around USD 15 billion by 2019.

The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by the physicians. The patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, in order to adjust the doses of insulin or change the medication if necessary, which is only possible with the use of self-monitoring blood glucose devices. According to the National Mortality Database, diabetes contributed to over 17,000 deaths in 2017 (11% of all deaths). Diabetes was the underlying cause of death in around 4,800 deaths (28% of diabetes deaths). It was an associated cause of death in further 12,200 deaths (72% of diabetes deaths). According to the ADA (American Diabetes Association), the total assessed cost for diagnosed diabetes in 2018 was around USD 333 billion, which was inclusive of USD 242 billion in direct medical costs and USD 91 billion in augmented productivity.

Scope of the Report

The report includes a complete study on self-monitoring blood glucose, which includes glucometer devices, blood glucose test strips, and lancets. The study is further divided into hospital usage and home usage.

Key Market Trends

Most of the Glucometer Market Revenue is Generated from Blood Glucose Test Strips.

The Glucometer is considered to be a one-time purchase. However, test strips, on the other hand, are considered to be a continuous investment, as a test strip needs to be disposed of after one use. Thus, it presents a considerable cost impact to the consumers. Overall, the global demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising global diabetic population. The growth in market volumes and share of the test strip is expected to be better than that of glucometers, because of the difference in the use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.

North America has the Largest Market Share with a CAGR 9% in forecast period.

It was estimated that North America held 12% of the total diabetes population, and also it held approximately 6% of total type-1 diabetes patients in 2019. The high diabetes prevalence in North America region is due to the combination of high population rate associated with high obesity and lifestyle changes. It is estimated that North America has 22% of the worldwide obesity population. There is more carbohydrate consumption among the countries in the region, which is also one of the leading causes of obesity. The prevalence of diabetes has increased dramatically during the past two decades, which is a fact-driven by the increased prevalence of obesity and lifestyle changes. In North America diabetes ranks among the fast-growing chronic diseases in the United States.

Competitive Landscape

The global self-monitoring blood glucose market is highly consolidated, with few major manufacturers having a global market presence, while the remaining manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that occurred between the players in the recent past helped the companies to strengthen their market presence. Panasonic acquired Bayer's diabetes care unit and named it as Ascensia diabetes care, which continued its operations all over the world.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Self-monitoring blood glucose devices
    • 5.1.1 By Component (Value, and Volume, 2012 - 2025)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 By End User
      • 5.1.2.1 Hospital Use (Value, and Volume, 2012 - 2025)
      • 5.1.2.1.1 Glucometer Devices
      • 5.1.2.1.2 Test Strips
      • 5.1.2.1.3 Lancets
      • 5.1.2.2 Personal Use (Value, and Volume, 2012 - 2025)
      • 5.1.2.2.1 Glucometer Devices
      • 5.1.2.2.2 Test Strips
      • 5.1.2.2.3 Lancets
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value, and Volume, 2012 - 2025)
      • 5.2.1.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.1.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.1.1.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
      • 5.2.1.2 Canada (Value, and Volume, 2012 - 2025)
      • 5.2.1.2.1 By Component (Glucometer Devices, Test Strips, Lancets)
      • 5.2.1.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.1.2.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
      • 5.2.1.3 Rest of North America (Value, and Volume, 2012 - 2025)
      • 5.2.1.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.1.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.1.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value, and Volume, 2012 - 2025)
      • 5.2.2.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.2 Germany (Value, and Volume, 2012 - 2025)
      • 5.2.2.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.3 Italy (Value, and Volume, 2012 - 2025)
      • 5.2.2.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.4 Spain (Value, and Volume, 2012 - 2025)
      • 5.2.2.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.4.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.5 United Kingdom (Value, and Volume, 2012 - 2025)
      • 5.2.2.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.5.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.6 Russia (Value, and Volume, 2012 - 20245
      • 5.2.2.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.6.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.2.7 Rest of Europe (Value, and Volume, 2012 - 2025)
      • 5.2.2.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.2.7.2 By End User (Hospital Use and Personal Use)
      • 5.2.2.7.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value, and Volume, 2012 - 2025)
      • 5.2.3.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.3.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.3.2 Brazil (Value, and Volume, 2012 - 2025)
      • 5.2.3.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.3.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.3.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.3.3 Rest of Latin America (Value, and Volume, 2012 - 2025)
      • 5.2.3.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.3.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.3.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value, and Volume, 2012 - 2025)
      • 5.2.4.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.2 South Korea (Value, and Volume, 2012 - 2025)
      • 5.2.4.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.3 China (Value, and Volume, 2012 - 2025)
      • 5.2.4.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.4 India (Value, and Volume, 2012 - 2025)
      • 5.2.4.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.4.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.5 Australia (Value, and Volume, 2012 - 2025)
      • 5.2.4.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.5.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.6 Vietnam (Value, and Volume, 2012 - 2025)
      • 5.2.4.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.6.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.7 Malaysia (Value, and Volume, 2012 - 2025)
      • 5.2.4.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.7.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.7.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.8 Indonesia (Value, and Volume, 2012 - 2025)
      • 5.2.4.8.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.8.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.8.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.9 Philippines (Value, and Volume, 2012 - 2025)
      • 5.2.4.9.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.9.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.9.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.10 Thailand (Value, and Volume, 2012 - 2025)
      • 5.2.4.10.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.10.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.10.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.4.11 Rest of Asia-Pacific (Value, and Volume, 2012 - 2025)
      • 5.2.4.11.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.4.11.2 By End User (Hospital Use and Personal Use)
      • 5.2.4.11.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
    • 5.2.5 Middle-East and Africa
      • 5.2.5.1 Saudi Arabia (Value, and Volume, 2012 - 2025)
      • 5.2.5.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.1.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.2 Iran (Value, and Volume, 2012 - 2025)
      • 5.2.5.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.2.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.3 Egypt (Value, and Volume, 2012 - 2025)
      • 5.2.5.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.3.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.4 Oman (Value, and Volume, 2012 - 2025)
      • 5.2.5.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.4.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.5 South Africa (Value, and Volume, 2012 - 2025)
      • 5.2.5.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.5.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.2.5.6 Rest of Middle-East and Africa (Value, and Volume, 2012 - 2025)
      • 5.2.5.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
      • 5.2.5.6.2 By End User (Hospital Use and Personal Use)
      • 5.2.5.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2025)
  • 6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Arkray
    • 7.1.5 Ascensia Diabetes Care
    • 7.1.6 Agamatrix Inc.
    • 7.1.7 Bionime Corporation
    • 7.1.8 Acon
    • 7.1.9 Medisana
    • 7.1.10 Trivida
    • 7.1.11 Rossmax

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q